+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Tuberculosis TB is a serious infectious disease caused by Mycobacterium tuberculosis, leading to millions of cases and deaths worldwide, particularly in developing countries like Nigeria. TB mainly affects the lungs and is worsened by HIV infection, making it a top cause of death globally. The trial investigates atorvastatin, a cholesterol-lowering drug, to see if it can improve TB treatment by reducing bacteria and lung damage, building on promising earlier studies that showed atorvastatin was safe and may enhance TB therapy outcomes. The trial is a phase IIC, multicenter, randomized, open-label study comparing four treatment groups three different daily doses of atorvastatin 20mg, 40mg, 60mg given for 16 weeks along with standard 6-month anti-TB therapy, and a control group receiving standard therapy alone. Patients are randomly assigned to one of these groups and followed closely for 12 months after starting treatment. The study aims to evaluate safety, the speed at which TB bacteria clear from sputum, improvement in chest X-rays, and lung function. Participants aged 12 to 65 with active pulmonary TB will undergo screening including medical history, HIV and diabetes testing, sputum cultures, blood tests, lung function, and pregnancy tests for women. During the study, sputum samples, blood tests, chest X-rays, and lung function will be monitored regularly. Researchers will track side effects and measure outcomes like TB disease-free survival and symptom improvement at 6 and 12 months. The long follow-up period allows for detailed assessment of treatment effects and safety.

Age: 12Years - 65YearsAll GendersPhase 2
8 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the implementation and scale-up of Nigerias national sodium reduction program led by the Nigerian Agency for Food and Drug Administration and Control NAFDAC. This program uses the WHOs SHAKE package, which includes strategies like surveillance of salt intake, industry engagement, labeling standards, consumer education, and promoting healthy eating environments to reduce sodium intake and prevent hypertension. The study uses a type III hybrid, mixed methods design to assess the programs progress and effectiveness in real-world settings. The study involves enrolling adult household representatives from three Nigerian states to participate in repeated waves of data collection. Participants take part in surveys such as the STEPs survey, provide 24-hour and spot urine samples, blood samples for fatty acid estimation, and complete multiple 24-hour dietary recalls. These assessments occur at baseline Wave 1, and follow-ups at around 18 months Wave 2 and 36 months Wave 3 to monitor dietary sodium sources, population sodium intake, and program implementation outcomes. Participants will be involved in interviews, surveys, and biological sample collections over the study period. Researchers will use various frameworks and methods to evaluate program reach, adoption, feasibility, fidelity, acceptability, and cost. Key outcomes include changes in mean population sodium intake and 24-hour urinary sodium from baseline through follow-up waves, along with shifts in dietary sources of sodium and knowledge, attitudes, and behaviors about sodium intake. The total participation period spans approximately three years, with repeated assessments to track progress and impact.

Age: 18Years - 69YearsAll Genders
3 locations
I

Actively Recruiting

Researchers are evaluating diabetes management within the Hypertension Treatment in Nigeria HTN 2.0 Program, building on prior success in hypertension care. The study focuses on 10 primary healthcare centers in Nigerias Federal Capital Territory that previously implemented hypertension treatment. This phase uses the WHO HEARTS-D bundle to improve diabetes screening, diagnosis, treatment, and control in these centers. The study compares a 12-month pre-implementation period, which involves registry setup and providing glucometers without diabetes treatment training, to a 24-month implementation period. During implementation, the centers receive HEARTS-D training for community health extension workers, expand drug availability including metformin and glimepiride, and receive quarterly supportive supervision with audit-and-feedback. Glucometers and supplies are replenished throughout the study. Participants include adults with or at risk for diabetes attending these centers. Researchers will monitor blood glucose control, diabetes treatment rates, and availability of diabetes medicines and equipment. Assessments include routine blood glucose measurements and registration of diabetes patients. Supportive supervision visits and training aim to improve care quality over 36 months, with outcomes measured by changes in blood glucose control and treatment adherence.

Age: 18Years +All GendersPhase Not Applicable
10 locations
G

Actively Recruiting

This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.

Age: 18Years +All Genders
76 locations
S

Actively Recruiting

Researchers are investigating the effects of pre-operative mouthwash and varying oxygen levels during surgery on the rates of pneumonia and surgical site infections in patients undergoing major abdominal surgery. This trial focuses on patients in low and middle-income countries, where postoperative complications are more common and often more severe. The study aims to find ways to reduce these serious complications, which can cause pain, disability, and increased healthcare costs. Participants will be randomly assigned to one of four groups pre-operative chlorhexidine mouthwash combined with high oxygen levels 80-100% FiO2, no mouthwash with high oxygen levels, mouthwash with low oxygen levels 21-30% FiO2, or no mouthwash with low oxygen levels. Treatments are given around the time of surgery, with oxygen delivered during the operation and mouthwash used before surgery. The study includes an internal pilot phase lasting six months to check recruitment and compliance, followed by a larger trial aiming to enroll nearly 13,000 participants. During the study, researchers will monitor participants for up to 30 days after surgery, assessing rates of pneumonia and surgical site infections using CDC definitions. They will also track other outcomes like mortality, repeat surgeries, hospital stay length, return to normal activities, critical care admissions, and healthcare resource use. Follow-up includes evaluating patient recovery and safety, with all data collected to understand how these interventions impact surgical outcomes in these settings.

Age: 10Years - 100YearsAll GendersPhase 3
37 locations